IVTCC 2.0: a Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Aug 17, 2020
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Sudden cardiac death (SCD), predominantly due to ventricular tachyarrhythmias, is a leading cause of mortality in the United States and around the world. Catheter ablation of ventricular arrhythmias has proven efficacious in reducing the burden of arrhythmias and reducing implantable cardiac defibrillator (ICD) shocks.
The aim of this study is to create a prospective international database registry that will allow for better assessment of the outcomes of catheter ablation of ventricular arrhythmias. The registry, with approximately 30 participating centers, will help to identify the overal...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - All patients undergoing catheter ablation for ventricular tachycardia (VT) or premature ventricular contractions (PVCs).
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Charleston, South Carolina, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Los Angeles, California, United States
Houston, Texas, United States
Aurora, Colorado, United States
Seattle, Washington, United States
Bronx, New York, United States
Sacramento, California, United States
Baltimore, Maryland, United States
San Francisco, California, United States
Chicago, Illinois, United States
Portland, Oregon, United States
Rochester, Minnesota, United States
Boston, Massachusetts, United States
Charlottesville, Virginia, United States
Nashville, Tennessee, United States
Philadelphia, Pennsylvania, United States
Rotterdam, , Netherlands
Milan, , Italy
Jerusalem, , Israel
Leiden, , Netherlands
New York, New York, United States
Saint Louis, Missouri, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Worcester, Massachusetts, United States
New York, New York, United States
York, Pennsylvania, United States
Gainesville, Florida, United States
Salt Lake City, Utah, United States
Hartford, Connecticut, United States
Phoenix, Arizona, United States
Kansas City, Kansas, United States
Baltimore, Maryland, United States
Ann Arbor, Michigan, United States
Minneapolis, Minnesota, United States
Austin, Texas, United States
Montréal, , Canada
Milan, , Italy
Koshigaya, , Japan
Madrid, , Spain
Wandsworth, , United Kingdom
Patients applied
Trial Officials
Jason Bradfield, MD
Principal Investigator
University of California, Los Angeles
Kalyanam Shivkumar, MD, PhD
Study Chair
University of California, Los Angeles
Paolo Della Bella, MD
Study Chair
San Raffaele Hospital, Italy
Francis Marchlinski, MD, FACC, FAHA, FHRS
Study Chair
University of Pennsylvania Health System
Andrea Natale, MD, FACC, FHRS, FESC
Study Chair
Texas Cardiac Arrhythmia Institute at St. David's Medical Center
William G Stevenson, MD
Study Chair
Vanderbilt Heart and Vascular Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials